Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tami Hunt

Optometrist Verona, WI Doctor of Optometry

NPI 1366416661 CMS profile 107461

320 S Main St, Verona, WI 53593

Open in the dashboard

General payments

$4,582

80 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tami Hunt of Verona, WI is reported in the CMS Open Payments database as having received $4,582 across 80 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $771 15
2024 General $507 11
2023 General $1,035 13
2022 General $153 4
2021 General $205 12
2020 General $110 6
2019 General $1,802 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tami Hunt
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Tami Hunt were reported at $771. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Tami Hunt Optometrist median Middle half National median
2019 $1,802 $159 $67–$371 $163
2020 $110 $72 $29–$165 $114
2021 $205 $125 $46–$292 $132
2022 $153 $162 $66–$374 $149
2023 $1,035 $177 $72–$406 $160
2024 $507 $188 $77–$427 $164
2025 $771 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch & Lomb, a division of Bausch Health US, LLC $1,807 21 payments
  2. Alcon Vision LLC $1,651 25 payments
  3. Bausch & Lomb Americas Inc. $675 19 payments
  4. LKC Technologies, Inc. $114 1 payment
  5. Allergan Inc. $100 1 payment
  6. CooperVision Inc. $68 4 payments
  7. Oyster Point Pharma, Inc. $47 2 payments
  8. Tarsus Pharmaceuticals, Inc. $39 2 payments
  9. Johnson & Johnson Vision Care, Inc. $29 2 payments
  10. Carl Zeiss Meditec AG $19 1 payment
  11. Other $33 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,943 67 payments
  2. Travel and Lodging $1,620 9 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,000 3 payments
  4. Gift $19 1 payment
Products named General payments · program years 2019–2025
  1. ULTRA $1,749 17 payments
  2. BIOTRUE $1,637 10 payments
  3. TOTAL30 $752 5 payments
  4. DAILIES TOTAL1 $612 3 payments
  5. INFUSE $591 21 payments
  6. Precision 1 $457 8 payments
  7. Air Optix Color $300 1 payment
  8. Precision7 $270 3 payments
  9. DAILIES $148 7 payments
  10. MIEBO $125 1 payment
  11. Other $525 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$8,151

Medicare's payments for the services billed

Medicare patients

111

Average age 74

Services billed

497

76 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 32%
Diabetes 23%
Depression 14%
Osteoporosis 14%
Ischemic heart disease 13%
Chronic kidney disease 11%
Cancer 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $39
$39 — —
TYRVAYA
  • Oyster Point Pharma, Inc. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

80 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record